Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes - Garcia-Manero G; Diez-Campelo M; Vellenga E; Jacoby MA; Merchan B; Breems D; Cortelezzi A; Doronin V; Gomez V; Beckers M; Della Porta MG; Varsos H; et al. (American Journal Of Hematology, 2021)